Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Operating Expenses (2016 - 2025)

Sunshine Biopharma's Operating Expenses history spans 14 years, with the latest figure at $6.4 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 2.89% year-over-year to $6.4 million; the TTM value through Dec 2025 reached $23.1 million, up 12.41%, while the annual FY2025 figure was $23.1 million, 11.88% up from the prior year.
  • Operating Expenses reached $6.4 million in Q4 2025 per SBFM's latest filing, up from $5.0 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $24.9 million in Q4 2022 to a low of $397842.0 in Q4 2021.
  • Average Operating Expenses over 5 years is $4.6 million, with a median of $4.4 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: soared 6161.52% in 2022, then tumbled 78.74% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $397842.0 in 2021, then surged by 6161.52% to $24.9 million in 2022, then tumbled by 78.74% to $5.3 million in 2023, then rose by 16.59% to $6.2 million in 2024, then increased by 2.89% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Operating Expenses are $6.4 million (Q4 2025), $5.0 million (Q3 2025), and $6.6 million (Q2 2025).